Saeed R. Khan

Saeed R. Khan

Auto-generated profile, based on publicly available information

Saeed R. Khan

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2009 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
SSShabana Shabbeer
Shabana Shabbeer
MSMichelle Sobolewski
Michelle Sobolewski
RARavi Kumar Anchoori
Ravi Kumar Anchoori
SKSushant Kachhap
Sushant Kachhap
MHManuel Hidalgo
Manuel Hidalgo
SKSaeed R Khan
Saeed R Khan
In recent years, various dietary components that can potentially be used for the prevention and treatment of cancer have been identified. In this study, we demonstrate that extract (FE) from the se...

15 May 2011 in Cancer Biology & Therapy
Verified
Journal Article
Open access
PDF file
RMRadharani Marik
Radharani Marik
MAMadhan Allu
Madhan Allu
RARavi Anchoori
Ravi Anchoori
VSVered Stearns
Vered Stearns
CUChristopher Umbricht
Christopher Umbricht
SKSaeed Khan
Saeed Khan
The estrogen receptor (ER) is a major target for the treatment of breast cancer cells. Genistein, a soy isoflavone, possesses a structure similar to estrogen and can both mimic and antagonize estrogen effects although at high concentrations it inhibits breast cancer cell proliferation. Hence, to enhance the anti-cancer activity of Genistein at lower concentrations, we have synthesized seven structurally modified derivatives of Genistein (MA-6, MA-8, MA-11, MA-19, MA-20, MA-21 and MA-22) based on the structural requirements for an optimal anti-cancer effect. Among those seven, three derivatives (MA-6, MA-8 and MA-19) showed high antiproliferative activity with IC 50 levels in the range of 1-2.5 μM, i.e., at much lower concentrations range than Genistein itself, in three ER-positive breast cancer cell lines (MCF-7, 21PT and T47D) studied. In our analysis, we noticed that at IC 50 concentrations, the MA-6, MA-8 and MA-19 Genistein derivatives induced apoptosis, inhibited ER-α messenger RNA expression and increased the ratio of ER-β to ER-α levels in a manner comparable to the parent compound Genistein. Of note, these three modified Genistein derivatives exerted their effects at concentrations 10-15 times lower than the parent compound, decreasing the likelihood of significant ER- α pathway activation, which has been a concern for Genistein. Hence these compounds might play a useful role in breast cancer chemoprevention. See commentary: Genistein: The future of prevention and treatment of breast cancer?

1 March 2008 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SKSrinivas K. Kumar
Srinivas K. Kumar
IRIndrajit Roy
Indrajit Roy
RARavi K. Anchoori
Ravi K. Anchoori
SFSarah Fazli
Sarah Fazli
AMAnirban Maitra
Anirban Maitra
SKSaeed R. Khan
Saeed R. Khan

1 February 2010 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
RYRoppei Yamada
Roppei Yamada
MKMaya B. Kostova
Maya B. Kostova
RARavi Kumar Anchoori
Ravi Kumar Anchoori
SXShili Xu
Shili Xu
NNNouri Neamati
Nouri Neamati
SKSaeed Khan
Saeed Khan
Paclitaxel (PTX) is a highly effective and cytotoxic agent widely used for the treatment of several solid tumors. However, PTX shows dose-limiting cytotoxicity and in most of the cases induces drug...

9 September 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RARavi Kumar Anchoori
Ravi Kumar Anchoori
MKMadeleine Susanne Quirine Kortenhorst
Madeleine Susanne Quirine Kortenhorst
MHManuel Hidalgo
Manuel Hidalgo
TSTaradas Sarkar
Taradas Sarkar
GHGurulingappa Hallur
Gurulingappa Hallur
SKSaeed R. Khan
Saeed R. Khan

3 August 2002 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AMAnnastasiah Mhaka
Annastasiah Mhaka
SDSam R Denmeade
Sam R Denmeade
WYWei Yao
Wei Yao
JIJohn T Isaacs
John T Isaacs
SKSaeed R Khan
Saeed R Khan